Structured Risk Assessment for First-in-Human Studies
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We describe a structured risk assessment and risk mitigation process that is currently used to evaluate proposed first-in human (FiH) studies. This process balances the inherent risks of an FiH study with maximal protection of subjects. Risk assessment should consider all available data, carefully identifying aspects that may lead to risk for healthy subjects. A structured risk assessment avoids omissions and promotes consistency. Such a risk assessment should be performed for Investigational Products as well as for challenge agents and study procedures. Careful risk assessment recognizes gaps of knowledge and emphasizes that FiH studies are tolerability, not toxicity, studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first edition of the guideline only referred to the EU Directive 2001/83/EC and its Annex and amendments [14], which apply to the request for authorisation of a clinical trial to competent authorities.”
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“In 2006 a first-in-human (FiH) study with a CD28-specific monoclonal antibody (TGN 1412) conducted at a Clinical Pharmacology Unit (CPU) in London, in the UK derailed in a life-threatening “cytokine storm” in all six healthy subjects receiving the starting dose.(1) Ten years later, in an FiH study with a small-molecul…”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“The two areas with the poorest correlation were hepatic effects and hypersensitivity/ cutaneous reactions.(25) An IB should not be a mere compilation(15) of summaries of compulsory preclinical studies,(26) but should include a comprehensive interpretation of the data.”
BackgroundThe contribution of latent human failures to the breakdown of complex systems
Reason, J. (1990) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1990.0090 · Cited by 762
More than the money: A review of the literature examining healthy volunteer motivations
Stunkel, L., & Grady, C. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.12.003 · Cited by 230 · cited 1×
“The protection of healthy subjects is even more in our hands since they may have personality characteristics that lead to higher risk-seeking behavior,(12,13) and they are primarily motivated by financial rewards.(14) Therefore, when designing and executing studies, we should adhere to the principle in the Declaration…”
Backgroundvan Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
What is there that is not poison? A study of the Third Defense by Paracelsus
Deichmann, W. B., Henschler, D., Holmstedt, B. R., & Keil, G. (1986) · Archives of Toxicology · doi:10.1007/bf00297107 · Cited by 146
Evolution and the growth process: Natural selection of entrepreneurial traits
Galor, O., & Michalopoulos, S. (2012) · Journal of Economic Theory · doi:10.1016/j.jet.2011.04.005 · Cited by 144
Black, R. E., Lau, W. K. K., Weinstein, R. J., Young, L. S., & Hewitt, W. L. (1976) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.9.6.956 · Cited by 124 · cited 1×
“Thus, we should not administer multiple doses of aminoglycosides to healthy subjects, knowing that permanent ototoxicity can occur within days of systemic application(9) in up to 24% of subjects.(10) The use of ear protection during dance parties may vary between countries; between societies and within a society, ther…”
MethodLedwith, B. J., & DeGeorge, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.273 · Cited by 120
The current status of biomarkers for predicting toxicity
Campion, S., Aubrecht, J., Boekelheide, K., Brewster, D. W., Vaidya, V. S., Anderson, L., Burt, D., Dere, E., Hwang, K., Pacheco, S., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827170 · Cited by 97 · cited 1×
“Although reliable safety biomarkers are not available for all organ toxicities, significant advances have been made in identification of biomarkers for toxicity, for instance, testes and liver.(33) There is a tendency to aim for control of a clinical study by using only rule-based stopping criteria.”
Background
Research works printed but not linked: 2
- Mezher M. EMA begins review of first-in-human trial safety following patient death, 2016. http://www.raps.org/Regulatory-Focus/News/2016/05/27/25030/EMA-Begins-Review-of-First-in-Human-Trial-Safety-Following-Patient-Death/. Accessed November 7, 2016.
- Peremans A. Need for a uniform European registration system for volunteer participation? Paper presented at: Joint Conference of European Human Pharmacology Societies, Berlin 2011.
Cited by
van Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
The Patient Motivation Pyramid and Patient-Centricity in Early Clinical Development
van Iersel, T. M., Courville, J., van Doorne, C., Koster, R. A., & Fawcett, C. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210427115820 · Cited by 8
Courville, J., Barber, A., & Fura, A. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70002 · Cited by 6
The Use of IC 50 for Potency and MTD as Objective in Study BIA 10–2474
van Iersel, M. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.995 · Cited by 2
Chaikin, P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1000 · Cited by 2
Metadata
- Authors
- van Iersel, M. T., Greenberg, H. E., & Westrick, M. L.
- Affiliations
- University of Wisconsin–Madison (US)
- Venue
- Therapeutic Innovation & Regulatory Science
- Published
- 2017-05
- Volume
- 51
- Issue
- 3
- Pages
- 288-297
- ISSN
- 2168-4790 (ISSN-L)
- 2168-4804
- OpenAlex
- W2610644622
- Cited by
- 7
- References
- 25
- Citations by year
- 2026: 1 · 2025: 1 · 2021: 1 · 2018: 1 · 2017: 3
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Therapeutic Innovation & Regulatory Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- first-in-human study, risk assessment, risk mitigation, healthy volunteers, investigational products
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structured Risk Assessment for First-in-Human Studies. https://app.cochat.ai/papers/10.1177/2168479017705156
- The paper
- van Iersel, M. T., Greenberg, H. E., & Westrick, M. L. (2017). Structured Risk Assessment for First-in-Human Studies. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1177/2168479017705156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.